Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

295 results about "Antigen presentation" patented technology

Antigen presentation describes a vital immune process which is essential for T cell immune response triggering. Because T cells recognise only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment, now bound to the major histocompatibility complex (MHC), is transported to the surface of the cell, a process known as presentation, where it can be recognized by a T cell receptor. If there has been an infection with viruses or bacteria, the cell will present an endogenous or exogenous peptide fragment derived from the antigen bound to MHC molecules. There are two types of MHC molecules which differ in the of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II). Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can finally recognise only ten to hundreds copies of a unique sequence of a single peptide among thousands of other peptides presented on the very same cell because MHC molecule in one cell can bind quite a large range of peptides.

Application of efonidipine in preparation of dendritic cell immunologic adjuvant

The invention relates to the technical field of cellular immunotherapy, in particular to application of efonidipine in preparation of a dendritic cell immunologic adjuvant. The invention provides an application of efonidipine in preparation of a dendritic cell immunologic adjuvant. It is found that efonidipine can promote maturation, migration and antigen presentation functions of DCs, and the homing ability of DCs and CD8 + T cell activation are remarkably improved. The activation aspect of efonidipine on DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86, expression of a migration index CCR7, activation of CD8 + T cells by antigen presentation and the like. The efonidipine used in the invention is a drug approved by FDA for clinical treatment of cardiovascular diseases, the application of the efonidipine in immunotherapy is found, new use of old drugs is realized, and the efonidipine has great economic value.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

CD40L-IL-2 fusion protein, preparation thereof and application of CD40L-IL-2 fusion protein in preparation of medicine for treating tumors

The invention discloses a CD40L-IL-2 fusion protein, preparation thereof and application of the CD40L-IL-2 fusion protein in preparation of drugs for treating tumors. The fusion protein comprises a CD40L trimer or a variant thereof, and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.
Owner:SHANGHAI CHEST HOSPITAL

Universal HLA antigen presentation prediction method and system based on protein language model and multi-modal neural network

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.
Owner:WUHAN HUADA ZHIYAN TECHNOLOGY CO LTD +1

Method for cryopreserving mature dendritic cells

The invention discloses a method for cryopreserving mature dendritic cells, and the method for cryopreserving the mature dendritic cells comprises a dendritic cell cryopreservation solution. The dendritic cell cryopreservation liquid is mainly prepared from the following raw materials in percentage by volume: 15 to 16v / v percent of human albumin injection, 1 to 3v / v percent of antifreeze protein liquid, 17 to 20v / v percent of compound dextran 40 injection, 17 to 20v / v percent of compound electrolyte injection and 41 to 50v / v percent of CryoStorCS10, in addition, the cryopreservation liquid also comprises Setanaxib, and the concentration of the Setanaxib in the cryopreservation liquid is 20 [mu] mol / L. The cryopreservation liquid is used for cryopreservation treatment of the mature dendritic cells, through synergistic interaction among different components in the cryopreservation liquid, the recovery survival rate of the cryopreserved mature dendritic cells is larger than or equal to 80%, and the antigen presentation capacity of the mature dendritic cells can be preserved to a large extent.
Owner:GZ RUNSHENG CYTOMED TECH CO LTD

Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer

PCT designated stage expiredWO2024238486A2Organic active ingredientsAntineoplastic agentsStage tumorCD8
Described herein is the combination of STING / TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4 / 6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.
Owner:UNIV OF MASSACHUSETTS

Tumor cell vaccine as well as preparation method and application thereof

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Antigen peptide polymer vesicle tumor vaccine as well as preparation method and application thereof

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.
Owner:SUZHOU UNIV

Immune epitope prediction method based on antigen presentation and immunogenic feature fusion

The invention provides an immune epitope prediction method based on antigen presentation and immunogenicity feature fusion. The method comprises the following steps: extracting peptide fragments and I-type human leukocyte antigen protein features from an immune epitope database by using a constructed feature extraction module; inputting the peptide fragment and the I-type human leukocyte antigen protein characteristics into a pre-trained antigen presentation prediction model, and obtaining the antigen presentation probability based on the antigen presentation prediction model; and inputting the peptide fragment, the I-type human leukocyte antigen protein characteristics and antigen presentation probability information into an immunogenicity prediction model to realize fusion of antigen presentation and immunogenicity characteristics, and obtaining an immunogenicity score representing the T cell activation probability of the peptide fragment based on the immunogenicity prediction model, thereby realizing prediction of the immunoepitope. According to the invention, the prediction precision of the immune epitope is improved.
Owner:TSINGHUA UNIVERSITY

Antisense long noncoding RNAS for the modification of gene expression and for therapeutic applications

PCT designated stage expiredWO2025011876A2DNA/RNA fragmentationVaccinationgenomic DNA
The present invention relates to an antisense long non-encoding RNA (aslncRNA) that may form a partial double stranded (ds) complex with a corresponding cellular mRNA in eukaryotic cells and to a biological complex comprising the antisense lncRNA and a target mRNA that may together form a partial double stranded complex in vitro. The dsRNA complex is preferentially exported from the nucleus and translated in the cytoplasm and thereby gene expression is boosted. In addition to boosting aslnc-RNAs inhibitiory aslnc RNAs are disclosed. An expression vector comprising a nucleic acid sequence of the aslncRNA is also disclosed. The present invention can be used to increase or decrease export of a target mRNA from the nucleus and thus, to increase or decrease gene expression without interfering with genomic DNA or with mRNA levels. Methods to increase or decrease the export and / or expression of a target mRNA, cell transfections using plasmids expressing the antisense lncRNA or using conjugates comprising the aslncRNA, and a pharmaceutical composition comprising the as-lncRNA are also disclosed. The aslncRNA, the complex, the expression vector, and the conjugate are useful for enhancing the production of recombinant proteins that are used in biotechnological applications and for medical purposes. The aslncRNA is also useful for increasing antigen presentation upon mRNA vaccination.
Owner:GEORG AUGUST UNIVERSITAT GOTTINGEN STIFTUNG OFFENLICHEN RECHTS

General preparation method of exosome for presenting tumor antigen and highly activating T cells

ActiveCN119040262Aguaranteed dosebest load efficiencyBacteriaMicroorganism based processesDendritic cellIndividualized treatment
The invention relates to a general preparation method of an exosome for presenting tumor antigen and highly activating T cells, and belongs to the technical field of biomedicine and immunotherapy. Aiming at the problems of low antigen presentation efficiency, insufficient T cell activation and high individualized treatment cost in the existing tumor immunotherapy method, the method disclosed by the invention comprises the following steps: firstly, synthesizing a tumor antigen specific nano stimulant capable of activating dendritic cells, so that the dendritic cells carry IFN-beta; and specific tumor-associated antigens and costimulatory molecules are expressed. And then, extracting the exosome from the dendritic cell culture supernatant. According to the preparation method disclosed by the invention, the efficiency of the exosome as an antigen presenting carrier is remarkably improved, T cells are effectively and specifically stimulated, the preparation cost is also reduced, a more effective general solution is provided for tumor immunotherapy, and the preparation method has a wide application prospect and clinical value.
Owner:BEIJING INST OF TECH +1

Giant salamander immunoregulation meat peptide and application thereof

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.
Owner:TSINGHUA SHENZHEN INTERNATIONAL GRADUATE SCHOOL

Lactoferrin composition and application thereof for improving immunity by regulating macrophage immune activity

The present invention discloses a lactoferrin composition and its application for improving immunity by regulating macrophage immune activity, and belongs to the technical field of functional compositions. The present invention obtains a lactoferrin composition with regulating macrophage immune activity by compounding lactoferrin, α-lactalbumin, N-acetylneuraminic acid and yeast β-glucan in a specific ratio, the raw material of the composition is easy to obtain, and four components work together to significantly enhance its phagocytic activity without changing the activity of macrophages, regulate the polarization state of macrophages in inflammatory response, inhibit macrophages from polarizing to pro-inflammatory M1 type, and promote macrophages to polarize to anti-inflammatory M2 type; At the same time, the composition can also enhance the antigen presentation ability of macrophages and the activation of immune T cells, and improve body immunity. Therefore, the composition provided by the present invention can be used to prepare health products, food or medicines, etc. that improve immunity.
Owner:HANGZHOU QIANDAOHU KANGNUOBANG HEALTH PROD CO LTD

CKS1B as immunotherapy response prediction biomarker and application thereof

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Glucan-modified bionic nanoparticles as well as preparation method and application thereof

The invention discloses a glucan modified bionic nanoparticle as well as a preparation method and application thereof. Preparing nanoparticles based on PLGA as an inner core; the tumor cell membrane is extracted from B16F10 melanoma cells and is used as an outer capsid; glucan is coupled with a hydrophobic long chain through reductive amination and is modified on the surface of a biomimetic nanoparticle cell membrane through a hydrophobic effect. The dextran nano delivery system is successfully constructed, cell membrane specific antigens and dextran are efficiently and jointly delivered to lymph nodes, tumor cell membranes provide epitopes for immune activation of nanoparticles, and beta-dextran provides molecular support for nanoparticle targeting immune cells. In-vivo and in-vitro activity experiments prove that the glycolipid modified bionic nanoparticles can effectively activate innate immunity through macrophages and NK cells, can promote dendritic cell antigen presentation, and initiate potent adaptive immune response. The bionic nanoparticles have huge development potential of novel tumor vaccines, and a new thought is provided for immunotherapy of cancers.
Owner:OCEAN UNIV OF CHINA

Preparation method of novel PEDV (porcine epidemic diarrhea virus) subunit vaccine

The invention provides a preparation method of a novel PEDV (porcine epidemic diarrhea virus) subunit vaccine, and belongs to the technical field of biology. The novel PEDV subunit vaccine is prepared by adopting a method comprising the following steps: (1) treating lactococcus lactis by using a high-pressure damp-heat method to obtain peptidoglycan particles; (2) treating the peptidoglycan particles by adopting an ultrahigh-pressure microjet technology to obtain a peptidoglycan carrier with the particle size of 280-850nm; and (3) mixing the peptidoglycan carrier with a PEDV subunit antigen of which the amino acid sequence is SEQ ID NO: 1 to obtain the novel PEDV subunit vaccine. The novel PEDV subunit vaccine comprises a peptidoglycan carrier with a specific size, can improve the in-vivo presentation efficiency of an antigen and rapidly induce efficient body fluid and mucous membrane immune response, and is of great significance to research and development of vaccines for porcine epidemic diarrhea diseases and the like.
Owner:JIANGSU ACAD OF AGRI SCI +1

Application of probiotic yeast microcapsules in drugs for treating immune diseases related to macrophage immunoregulation

The invention discloses application of probiotic yeast microcapsules in drugs for targeted regulation of inflammatory macrophage immunity, and belongs to the technical field of biological medicines. As a novel medicine, the yeast microcapsule has the characteristics of engineering, convenience, low cost, high patient compliance, high safety and excellent targeting property, can be used as an oral medicine for treating chronic inflammatory disease rheumatoid arthritis, acts on mitochondria through oxidative stress and oxidative phosphoric acid pathways, inhibits excessive activation of macrophages, and has the effect of treating chronic inflammatory disease rheumatoid arthritis. Release of inflammatory factors is reduced, and inflammatory reaction is relieved; the yeast micro-capsule can promote the phagocytosis and antigen presentation function of macrophages and enhance the immune defense capability of a body, so that the immune function of the macrophages is adjusted, and the yeast micro-capsule shows huge potential in preparation of drugs for targeted adjustment of inflammatory macrophage immunity, and has a broad application prospect in preparation of drugs for targeted adjustment of inflammatory macrophage immunity. And a theoretical basis is provided for developing non-invasive, convenient and safe treatment of chronic inflammatory diseases such as rheumatoid arthritis.
Owner:SECOND AFFILIATED HOSPITAL OF COLLEGE OF MEDICINEOF XIAN JIAOTONG UNIV

Calcium-doped manganese phosphate engineered erythrocyte based on biomimetic mineralization technology and application of calcium-doped manganese phosphate engineered erythrocyte in immunotherapy

The invention belongs to the technical field of cellular immunity, and particularly relates to calcium-doped manganese phosphate engineered red blood cells based on a biomimetic mineralization technology and application of the calcium-doped manganese phosphate engineered red blood cells in immunotherapy. Calcium ions, manganese phosphate, acidic polypeptide and a carboxyl activator are deposited on the surfaces of red blood cells, the acidic polypeptide provides a negative electricity environment, the concentration of calcium and manganese on red blood cell membranes is increased, and a mineralization layer of calcium ions and manganese ions is formed; the carboxyl activator can activate carboxyl of amino acid on acidic polypeptide and is covalently bound with other molecules; calcium can improve the stability of the manganese phosphate crystal, optimize the release of manganese ions and activate a cGAS-STING pathway in the DC; the natural half-life period of red blood cells reaches 120 days, rapid clearing of the liver can be avoided, the aged red blood cells are swallowed by spleen DC, and cross presentation of antigens is promoted. The calcium-doped manganese phosphate engineered erythrocyte provided by the invention can promote the maturation, migration, homing and antigen presentation functions of dendritic cells, and enhance the ability of the dendritic cells to activate CD8 + T cells.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Nucleic acid tetrahedron nanostructure and preparation method and application thereof

The invention discloses a nucleic acid tetrahedron nanostructure as well as a preparation method and application thereof. The nucleic acid tetrahedron nanostructure is composed of circRNA for coding an antigen, an ISD chain and two specific single-stranded DNA sequences, is simple and easy to prepare, can enter cells through cell membrane microfossa mediated endocytosis without the help of a transfection reagent, and is positioned to lysosome. The nanostructure is split to release circRNA coding antigen protein, and the circRNA coding antigen protein is delivered to APC and ISD chains in drainage lymph nodes (dLN) to activate cGAS-STING pathways, so that antigen presentation and immune activation are synergistically enhanced, T cells are efficiently and continuously activated, and the effect of tumor immunotherapy is achieved.
Owner:ZHEJIANG UNIV OF TECH

Tumor avatar vaccine compositions and uses thereof

PendingUS20240398865A1Lipid/lipoprotein ingredientsDepsipeptidesDendritic cellDendrite
Disclosed herein are methods of eliciting an anti-cancer immune response by administering tumor-associated antigens, cells containing tumor-associated antigens, and / or nucleic acids encoding tumor-associated antigens. inducing immunogenic cell death in the cells expressing or containing the tumor-associated antigens. and optionally generating hyperactivated dendritic cells. Expression of tumor-associated antigens in a separate anatomical site generates a tumor avatar, which mimics the antigenic, but not immunosuppressive, environment of the tumor, with the generation of hyperactivated dendritic cells enhancing antigen presentation to elicit a robust anti-tumor T cell and antibody response. Also provided are compositions and kits containing nucleic acids and other components for use in the methods provided herein.
Owner:THE GENERAL HOSPITAL CORP +2

Nucleic acid molecules, fusion proteins, and mRNA vaccines with enhanced antigen presentation by recruiting ligands

The present invention relates to the field of biomedicine, and mainly relates to a vaccine design method for enhancing an antigen-presenting effect. A target antigen and a ligand such as a polypeptide or a protein domain having an E3 ubiquitin ligase binding or recruitment function are jointly coded in a same nucleic acid sequence, thereby promoting the degradation of the antigen protein by means of a proteasome approach, increasing the number and abundance of antigen peptides having antigen epitopes, and forming more peptide-MHC (p-MHC) complexes, and the complexes are presented on the surfaces of the cells, thereby enhancing subsequent immune response, and exerting an efficient tumor immunotherapy effect. The nucleic acid, the protein and the polypeptide vaccine provided have an efficient antigen-presenting effect and strong immunogenicity, and have good clinical application prospects.
Owner:WESTGENE BIOPHARMA CO LTD

Engineering bionic dendritic cell vesicle coupled antigen peptide tumor vaccine as well as preparation method and application thereof

The invention provides an engineered bionic dendritic cell vesicle coupled antigen peptide tumor vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineered bionic dendritic cell vesicle provided by the invention is internally loaded with an agonist of an interferon gene stimulation receptor, and the surface of an outer membrane is coupled with a melanoma antigen peptide gp100. In the engineering bionic dendritic cell vesicle provided by the invention, the antigen peptide gp100 can trigger the hyperactivity of various immune cells such as DC at a lymph node part, the antigen presentation procedure of the DC is promoted, and the killing ability of effector T cells is enhanced; the interferon gene loaded in the vesicles stimulates agonists of receptors, so that immune cells can be promoted to be activated, the ability of the immune cells to recognize pathogens and abnormal cells is enhanced, meanwhile, various immune cells are induced to secrete I-type interferon, apoptosis of tumor cells is promoted, immune memory effects of the immune cells are promoted, and recurrence and metastasis of tumors are prevented.
Owner:SHANGHAI DERMATOLOGY HOSPITAL

Peptide-HLA class I allele affinity prediction system based on protein language model and dual multi-instance attention mechanism

The invention relates to the technical field of biological information and computational immunity, and discloses a peptide-HLA class I allele affinity prediction system based on a protein language model and a dual multi-instance attention mechanism. The prediction system comprises a peptide and human leukocyte antigen HLA class I molecule sequence coding and distributed expression module, a dynamic selection mechanism long short-term memory network LSTM multi-level feature extraction module, a dual multi-instance attention module and a feature fusion and affinity prediction module. According to the invention, for a molecular sequence containing HLA class I molecules and polypeptides, a self-trained epitope peptide protein language model and an HLA class I molecular protein language model are utilized to obtain a feature coding vector of an amino acid sequence so as to better characterize the molecular sequence; and for the dependence problem of variable lengths among amino acids, an improved dynamic selection mechanism LSTM is utilized to learn dependence characteristics among amino acids with different distances in a sequence, so that the beneficial effect of improving the prediction effect of HLA antigen presentation is achieved.
Owner:WUHAN KANGSHENG BEITAI BIOLOGICAL TECH CO LTD

Rice residue oligopeptide with immunosuppressive activity and application thereof

The invention belongs to the technical field of biochemistry, and discloses a rice residue oligopeptide with immunosuppressive activity, and the amino acid sequence of the rice residue oligopeptide with immunosuppressive activity is any one of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also discloses a preparation method of the rice residue oligopeptide with immunosuppressive activity. The rice residue oligopeptide with the immunosuppressive activity has a very good immunoregulation effect, particularly has an excellent anti-inflammatory effect and an excellent capability of promoting antigen presentation, and can be used as an immunomodulator for regulating the immune function of a body, inhibiting inflammation, resisting tumors and / or enhancing the vaccine effect. A new thought is provided for researching the action mechanism of the food-borne immunoactive peptide, and a theoretical basis is also provided for deep development of rice processing byproducts.
Owner:CHANGSHA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Method for preparing multifunctional nano-hydroxyapatite-based tumor vaccine by one-step method

The invention discloses a method for preparing a multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method, and relates to a preparation method of a nano-hydroxyapatite-based tumor vaccine. The invention aims to solve the problems of low antigen presentation efficiency of existing tumor vaccines and complex preparation process of nano vaccines based on tumor cell membranes. The preparation method comprises the following steps: 1, preparing small-particle-size calcium-based nanoparticles; and 2, synthesizing the HAP NV (at) DOX nano compound. The preparation method is used for preparing the multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method.
Owner:HARBIN ENG UNIV

Method for preparing HLA-A24:02 APC cells and application thereof

The application provides a kind of HLA-A24:02 APC cell preparation method and application, it is related to cell preparation technical field.The present application constructs the APC cell (K562-HLA-A24:02) that can replace HLA-A24:02 subtype DC cell, fills the blank of HLA-A24:02 subtype special engineering APC cell, and the cell can realize the antigen presentation function consistent with natural HLA-A24:02 subtype DC cell, provides special tool cell for the immune research for the HLA subtype;The present application constructs APC cell with K562 cell line as base, K562 cell can be in vitro permanent passage amplification, without repeatedly separating and inducing DC cell from human peripheral blood, reduces the use amount of peripheral blood, reduces the raw material dependence and cost of cell acquisition, while avoiding the influence of individual difference of peripheral blood source on experimental results.
Owner:赣州市人民医院 +1

Methods and compositions for identifying epitopes

Abstract Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell. Abstract 2018 / 22761 oM - cell Target ml Target cell cell cell Target Target Target SUBSTITUTE SHEET (RULE 26) cell cell cell Target Target cell cell 1 / 28 my Isolate recognized cell Library of target cells target cells and displaying different Add T cells from sample sequence antigens antigens of interest. CTLs deliver cytotoxic granules to target cells displaying cognate antigen FIG. 1 PCT / US2018 / 036663 20 26 20 53 56 07 J ul 2 02 6 2 0 2 6 2 0 5 3 5 6 0 7 J u l 2 0 2 6 2 0 1 8 / 2 2 7 6 1 o M a n d m y 1 / 2 8 m y L i b r a r y o f t a r g e t c e l l s d i s p l a y i n g d i f f e r e n tA d d T c e l l s f r o m s a m p l e of interest. CTLs deliver c y t o t o x i c g r a n u l e s t o t a r g e t c e l l s d i s p l a y i n g c o g n a t e a n t i g e n P C T / U S 2 0 1 8 / 0 3 6 6 6 3
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Drug combinations and evaluation methods for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy

PendingCN122351490ADendritic cellTumor response
This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV +1

Iterative radiation-resistant tumor cell debris as well as preparation method and application thereof in tumor resistance

The invention belongs to the technical field of cancer immunotherapy, and particularly relates to iterative radiation-resistant tumor cell debris, a preparation method thereof and an application thereof in tumor resistance. The anti-radiation tumor cells generated by repeated radiation exposure show higher TMB (Tetramethylbenzidine) and induce stronger immunoreaction, so that a personalized vaccine is developed based on the method, and the frozen fragment vaccine is obtained by freeze thawing and inactivation of the radiation-resistant tumor cells. The RR-FDV exhibits enhanced immunogenicity as compared to a conventional radiosensitive counterpart. In the present disclosure, RR-FDV exhibits superior activation of antigen presenting cells, while in vivo, it recruits more dendritic cells to the vaccination site, promotes DC-mediated antigen presentation, and induces stronger antigen-specific T cell toxicity.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Nucleic acid vaccine based on different forms of nano aluminum adjuvants and application of nucleic acid vaccine

The invention discloses a nucleic acid vaccine based on different forms of nano-aluminum adjuvants and application thereof, the nucleic acid vaccine is composed of an inner core, a middle layer and a shell from inside to outside in sequence, the inner core is a compound of a cationic polymer and nucleic acid, the middle layer is an anionic polymer, and the shell is a continuous or discontinuous nano-aluminum coating layer. The nano-aluminum-coated nucleic acid delivery system provided by the invention is used for preparing vaccines, can effectively activate antigen presenting cells and promote antigen presentation, so that humoral immunity and cellular immunity processes of an organism are simultaneously activated, the tumor immunotherapy effect is enhanced, and the nano-aluminum-coated nucleic acid delivery system has relatively high clinical use value.
Owner:CHINA PHARM UNIV